NCT05688215View on ClinicalTrials.gov

Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

March 7, 2023

Primary Completion Date

December 1, 2025

Study Completion Date

March 2, 2026

Conditions
Borderline Resectable Pancreatic AdenocarcinomaLocally Advanced Pancreatic Ductal Adenocarcinoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo collection of blood and tissue samples

PROCEDURE

Computed Tomography

Undergo a CT scan

PROCEDURE

Core Biopsy

Undergo core biopsy

DRUG

Fluorouracil

Given IV

DRUG

Irinotecan

Given IV

DRUG

Leucovorin

Given IV

DRUG

Leucovorin Calcium

Given IV

DRUG

Oxaliplatin

Given IV

DRUG

Quemliclustat

Given intravenously (IV)

DRUG

Zimberelimab

Given IV

Trial Locations (1)

90095

RECRUITING

Yonemoto,Lisa, Los Angeles

Sponsors

Collaborators (1)

Arcus Biosciences, Inc.
All Listed Sponsors
collaborator

Arcus Biosciences, Inc.

INDUSTRY

lead

Jonsson Comprehensive Cancer Center

OTHER

NCT05688215 - Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma | Biotech Hunter | Biotech Hunter